
Oncologist

No OPD information available
Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
EGFR Positive Lung Cancer
Cerebral Hypoxia
Mesothelioma
Tissue Biopsy
Acquired Hemophilia
Ataxia-Telangiectasia
Brain Tumor
Breast Cancer
Colorectal Cancer
Diarrhea
Erythema Multiforme
Lung Adenocarcinoma
Metastatic Brain Tumor
Progeria
Prostate Cancer
Small Cell Lung Cancer (SCLC)
Stevens-Johnson Syndrome
Telangiectasia
Xeroderma Pigmentosum
Kenneth J. O'byrne is a male medical professional who specializes in treating various health conditions, including lung cancer, brain tumors, breast cancer, and more. He is known for his expertise in areas such as Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and Prostate Cancer. Kenneth J. O'byrne uses different treatments like tissue biopsies and targeted therapies to help his patients.
Kenneth J. O'byrne is a caring doctor who communicates well with his patients, making them feel heard and understood. Patients trust him because he takes the time to explain things in a way that is easy to understand and shows genuine concern for their well-being.
To stay updated with the latest medical knowledge and research, Kenneth J. O'byrne regularly attends conferences, reads scientific journals, and collaborates with other healthcare professionals. This helps him provide the best possible care to his patients based on the most current information available.
Kenneth J. O'byrne works closely with his colleagues and values teamwork in providing comprehensive care to patients. He believes in a collaborative approach to medicine, where different specialists work together to achieve the best outcomes for their patients.
Through his dedication and expertise, Kenneth J. O'byrne has positively impacted many patients' lives by improving their health outcomes and quality of life. His research on targeted therapies for lung cancer has been published in reputable medical journals, showcasing his contributions to the field of oncology.
In addition to his clinical work, Kenneth J. O'byrne is involved in ongoing clinical trials to explore innovative treatment options for patients with advanced solid tumors. His commitment to advancing medical knowledge and improving patient care is evident in his participation in research studies aimed at finding new and effective therapies.
Enrollment Status: Recruiting
Published: July 19, 2024
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
